by Federico Graciano, Duke-NUS Medical School Graphical abstract. Credit: Journal of the American Society of Nephrology (2022). DOI: 10.1681/asn.2021040577 A treatment strategy using an antibody that inhibits a cell signaling protein called interleukin-11 (IL-11) could lead to new hope for people with a debilitating genetic kidney disease called Alport syndrome. Scientists from Duke-NUS Medical School, Singapore, reported...
